Home / Research & Trials / Gulbarga

Sl. No. Principal Investigator’s Name Study Title Phase Protocol ID Indication Study Status Contact person & Phone Number
1 Dr Nandish Kumar “A Global, multicentre, three arms, and open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension Compared to Taxotere (Docetaxel Injection Concentrate) in triple – negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.” TNBC Ongoing Dr Abhishek 9902040230
2 Dr Nandish Kumar A Phase IIb/III, Randomised, Double-blind, Placebo-controlled, Multicentre, Study of CA-170 in Combination with Chemotherapy and Radiation in Patients with Unresectable Stage III or IVa Non-Squamous Non-Small Cell Lung Cancer (ASIAD-2)” Phase 2b/3 CA-170-302 NSCLC Ongoing Dr Abhishek 9902040230
3 Dr Nandish Kumar A Phase 3, Open-label, Randomized study of Dato-DXd versus Investigator’s choice of chemothetapy in participants with inoperable or Metastatic Hormone Receptor-Positive, HER-2 Negative breast cancer who have beentreated with one or two prior lines of Systemic Chemotherapy (TROPION-Breast01) Phase 3 D9268C00001 ER+ve HER-Ve SIV Pending Dr Abhishek 9902040230
4 Dr Nandish Kumar A Phase II Open-Label Trial Evaluating the Efficacy and Safety of Once Daily Oral ODM-203 in Patients with Unresectable Transitional Cell Urothelial Carcinoma with FGFR3 Mutation (TEJAS-1) Phase 2 ODM-201 Ca Ovary EC Pending Dr Abhishek 9902040230

To get in touch with the Clinical Trials Team at HCG, please call on +91 80 4020 6000 (extn: 6058)

Research and Trials

To know more about facilities available for patients at HCG

HCG Call Icon